Search results
Author(s):
Lars H Lund
Added:
1 year ago
Prof Lars Lund (Karolinska Institute, SE) outlines the findings of the ALLEVIATE-HF-1 and ALLEVIATE-HF-2 studies at 6 months. Presented at Heart Failure 22, this study aimed to evaluate a no-implant shunt in patients with chronic heart failure.
Discussion Points:
1. Aims of This Study
2. No-Implant Interatrial Shunt
3. Inclusion and Exclusion Criteria, Patient Cohort and Study Design
4. Key…
View more
Author(s):
Ify R Mordi
,
Aaron Tee
,
Chim C Lang
Added:
3 years ago
Despite advances in the management of heart failure (HF), a significant burden of mortality and morbidity remains.1 This, combined with the ever-escalating costs of novel drug development, has led to an increased focus on the treatment of comorbidities in order to improve outcomes. As a chronic condition, it is increasingly recognised that HF is actually an iron-deficient state, and is highly…
View more
Foreword
Author(s):
Andrew JS Coats
,
Giuseppe Rosano
Added:
3 years ago
Article
Author(s):
Giuseppe Rosano
,
David Quek
,
Felipe Martínez
Added:
3 years ago
Heart failure (HF) is a shared chronic phase of many cardiac diseases, including ischaemic heart disease, chronic obstructive pulmonary disease and hypertension. It is characterised by structural or functional impairment of ventricular filling or ejection of blood from the heart.1–3 It is estimated that there are more than 37.7 million cases of HF globally and its prevalence is on the rise.2 HF…
View more
Author(s):
Kiran K Mirza
,
Finn Gustafsson
Added:
3 years ago
According to the third report from the International Society for Heart and Lung Transplantation (ISHLT) Mechanically Assisted Circulatory Support Registry, more than 15,500 left ventricular assist devices (LVADs) were implanted worldwide between 2013 and 2017.1 Originally, LVADs were exclusively implanted as part of a bridge to transplantation (BTT) strategy, but in recent years a large…
View more
Author(s):
Sabina Frljak
,
Gregor Poglajen
,
Bojan Vrtovec
Added:
2 years ago
SGLT2 Inhibitors in HFpEF
Author(s):
Brent Deschaine
,
Sahil Verma
,
Hussein Rayatzadeh
Added:
1 year ago
Article
Author(s):
Tonje Thorvaldsen
,
Lars H Lund
Added:
3 years ago
Heart failure (HF) is associated with poor quality of life, high risk of death and is the leading cause of hospitalisation.1 With an ageing population and improved care for cardiovascular diseases, the prevalence of HF is increasing. Despite advances in HF therapies, 1–10% of the population with HF progress to an advanced stage of the disease.2,3 In the US, an estimated 250,000–300,000 patients…
View more
Author(s):
Marco Metra
,
Elisabetta Dinatolo
,
Nicolò Dasseni
Added:
3 years ago
Despite improvements in treatment, heart failure (HF) continues to have a progressive clinical course characterised by worsening of cardiac function and clinical condition, leading to a stage of advanced chronic HF. At this stage, the clinical picture is characterised by severe symptoms, frequent episodes of decompensation, poor quality of life and poor survival. Evidence-based medical treatments…
View more
Author(s):
Lampros Papadimitriou
,
Charles K Moore
,
Javed Butler
,
et al
Added:
4 years ago
Heart failure (HF) is a global epidemic which affects about 6 million adults in the US. It is projected that by 2030 the total cost of HF will reach US$70 billion. Despite the development of novel drugs and devices, the mortality burden of HF remains high, with one in three patients dying within 1 year of hospitalisation for HF and 40–50% within 5 years of diagnosis.1
Patients with HF are…
View more